Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
about
Site-specific metabolic phenotypes in metastatic breast cancer.Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobinUpdate on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studiesCytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Expression of high affinity folate receptor in breast cancer brain metastasis.Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study.Molecular and diagnostic features of apocrine breast lesions.The clinicopathologic features of molecular apocrine breast cancer.Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.Breast cancer subtypes: morphologic and biologic characterization.Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status.Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
P2860
Q34788659-030CE386-3370-42AF-AE33-BB85D9BDCB90Q35155568-DAA4AD89-CD63-4F0B-BDA3-63BCEC00AAE9Q35573116-4F6B0F40-6C3B-4FE0-B985-DAF20C2AA7CEQ35740160-9DBA1750-5940-4030-AE74-BC43D1DF83B8Q36557588-EFA6264E-B15E-4978-98B3-0706D65C8896Q38390445-53A053AD-DC56-45E8-B830-0F2BE802D705Q38537958-A63A8B95-1CDD-4E6D-AFF1-902DAB82CED4Q41844454-3555A76E-47A3-4E71-A0EF-D6902933F00BQ45766039-572E368E-665E-4AD3-AE44-10C7AE9D86D7Q49320962-3111E888-7C9E-44E0-A8AA-3FF4CED4081BQ53438825-D7F236C3-8E4D-427E-97B9-3D17D2FFB4A0Q54284515-7B74595B-1402-46D4-A77C-7ACA7AE1E074Q54324778-A2BECD82-51DE-4883-8417-AC655E4665DAQ54350939-BDEF970D-23D1-4B80-B709-0DAF41B49A2AQ54353219-4B36F8FC-FF90-45C2-A924-2102F669B7D4Q54638064-773B2A19-C081-4B0B-91B9-21AE8CB81EC2
P2860
Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@en
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@nl
type
label
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@en
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@nl
prefLabel
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@en
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@nl
P2093
P1476
Breast cancer molecular class ...... markers CK5, CK5/6, and EGFR.
@en
P2093
David J Dabbs
Joan M Striebel
Rohit Bhargava
Sushil Beriwal
P304
P356
10.1097/PAI.0B013E3181B94FF1
P577
2010-03-01T00:00:00Z